⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL684126 | 0.80 | HRH3 (0.41) | — | |
| SCHEMBL734698 | 0.80 | HRH3 (0.41) | — | |
| SCHEMBL8434577 | 0.80 | HRH3 (0.41) | — | |
| SCHEMBL23137396 | 0.79 | GBA1 (0.39) | — | |
| SCHEMBL18021206 | 0.79 | — | — | |
| SCHEMBL255944 | 0.77 | SIGMAR1 (0.36) | — | |
| SCHEMBL12568633 | 0.77 | SIGMAR1 (0.36) | — | |
| SCHEMBL17946411 | 0.76 | — | — | |
| SCHEMBL18863688 | 0.76 | — | — | |
| SCHEMBL20711869 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-11548890-B1 | HPK1 antagonists and uses thereof | Nimbus Saturn, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11530199-B2 | Analogs for the treatment of disease | INSILICO MEDICINE IP LIMITED (HK) | 2022-12-20 | — | — | US | disclosed |
| WO-2022192598-A1 | HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | CORVUS PHARMACEUTICALS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| WO-2022025880-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| US-11091462-B2 | (Hetero)arylamide compound for inhibiting protein kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2021-08-17 | — | — | US | disclosed |
| EP-3838897-A2 | (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | Shenzhen TargetRx, Inc. (CN) | 2021-06-23 | — | — | EP | disclosed |
| US-11021481-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists | Nimbus Saturn, Inc. (US) | 2021-06-01 | — | — | US | disclosed |
| WO-2020160192-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| US-20190248767-A1 | Tetrahydroquinazoline Derivatives Useful as Anticancer Agents | PFIZER INC. (US) | 2019-08-15 | — | — | US | disclosed |
| US-20190233440-A1 | Substituted Quinazoline and Pyridopyrimidine Derivatives Useful as Anticancer Agents | PFIZER INC. (US) | 2019-08-01 | — | — | US | disclosed |
| US-10246478-B2 | Polyene macrolide derivative | SHIONOGI & CO., LTD. (JP) | 2019-04-02 | — | — | US | disclosed |
| WO-2019046784-A1 | COMPOUNDS AND METHODS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR | CORVUS PHARMACEUTICALS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| WO-2017120164-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Tabomedex Biosciences, LLC (US) | 2017-07-13 | — | — | WO | disclosed |
| US-20170190729-A1 | POLYENE MACROLIDE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| EP-3156410-A1 | POLYENE MACROLIDE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2017-04-19 | — | — | EP | disclosed |
| WO-2013018804-A1 | URACIL DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | 大日本住友製薬株式会社 (JP) | 2013-02-07 | — | — | WO | disclosed |
| US-20120115819-A1 | Pentacycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-10 | — | — | US | disclosed |